89bio 미래 성장
Future 기준 확인 2/6
89bio is forecast to grow earnings and revenue by 18.3% and 81.8% per annum respectively. EPS is expected to grow by 23.3% per annum. Return on equity is forecast to be -131.1% in 3 years.
주요 정보
18.3%
수익 성장률
23.3%
EPS 성장률
Biotechs 수익 성장 | 27.1% |
매출 성장률 | 81.8% |
향후 자기자본 수익률 | -131.1% |
애널리스트 커버리지 | Good |
마지막 업데이트 | 13 Sep 2024 |
최근 미래 성장 업데이트
Recent updates
89bio: Surviving A Competitive Space - For Now
Oct 29Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?
Sep 2689bio: Bullish In Light Of Further MOA Being Established By Peer
Aug 0789bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
May 2389bio Still Has A Chance As NASH Race Heats Up
Oct 0689bio completes enrollment in phase 2 trial for NASH treatment
Aug 1889Bio rallies on Deep Track Capital disclosing 10% stake
Jul 0789bio: Undervalued Contender In Race For First NASH Drug Approval
Jul 20We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
May 0789bio: NASH Drug Developer With Differentiated Profile
Jan 29We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
Jan 2289bio expects to initiate Phase 2b NASH trial in 1H21
Jan 05수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2026 | 26 | -287 | -320 | -318 | 7 |
12/31/2025 | 3 | -274 | -283 | -310 | 7 |
12/31/2024 | 1 | -230 | -196 | -234 | 7 |
6/30/2024 | N/A | -175 | -166 | -166 | N/A |
3/31/2024 | N/A | -165 | -139 | -139 | N/A |
12/31/2023 | N/A | -142 | -129 | -129 | N/A |
9/30/2023 | N/A | -127 | -122 | -122 | N/A |
6/30/2023 | N/A | -119 | -106 | -106 | N/A |
3/31/2023 | N/A | -105 | -87 | -87 | N/A |
12/31/2022 | N/A | -102 | -81 | -81 | N/A |
9/30/2022 | N/A | -104 | -82 | -82 | N/A |
6/30/2022 | N/A | -105 | -81 | -81 | N/A |
3/31/2022 | N/A | -101 | -86 | -86 | N/A |
12/31/2021 | N/A | -90 | -77 | -77 | N/A |
9/30/2021 | N/A | -76 | -63 | -63 | N/A |
6/30/2021 | N/A | -63 | -62 | -62 | N/A |
3/31/2021 | N/A | -54 | -54 | -53 | N/A |
12/31/2020 | N/A | -49 | -46 | -46 | N/A |
9/30/2020 | N/A | -56 | -44 | -43 | N/A |
6/30/2020 | N/A | -60 | -37 | -37 | N/A |
3/31/2020 | N/A | -64 | -29 | -29 | N/A |
12/31/2019 | N/A | -57 | -26 | -25 | N/A |
9/30/2019 | N/A | -44 | -19 | -19 | N/A |
6/30/2019 | N/A | -30 | -15 | -15 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: ETNB is forecast to remain unprofitable over the next 3 years.
수익 vs 시장: ETNB is forecast to remain unprofitable over the next 3 years.
고성장 수익: ETNB is forecast to remain unprofitable over the next 3 years.
수익 대 시장: ETNB's revenue (81.8% per year) is forecast to grow faster than the US market (8.9% per year).
고성장 수익: ETNB's revenue (81.8% per year) is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: ETNB is forecast to be unprofitable in 3 years.